Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 8/20 | 0.35 |
| ▸ | LCK | P06239 | 5/20 | 0.35 |
| ▸ | KDR | P35968 | 5/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17814174 | 0.78 | DYRK1A (0.39) | CYP11B1CYP11B2PDCD1CD274FASN | |
| SCHEMBL17814091 | 0.75 | NPC1 (0.44) | CYP11B1CYP11B2 | |
| SCHEMBL17814119 | 0.74 | CYP11B1 (0.41) | CYP11B1CYP11B2PDCD1CD274 | |
| SCHEMBL17814205 | 0.73 | CYP11B1 (0.44) | CYP11B1CYP11B2KDRPIM1PIM2 | |
| SCHEMBL19361099 | 0.73 | DYRK1A (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL17814175 | 0.73 | CYP11B1 (0.38) | CYP11B1CYP11B2CTSC | |
| SCHEMBL17814125 | 0.73 | CYP11B1 (0.39) | CYP11B1CYP11B2LCKKDR | |
| SCHEMBL17814177 | 0.72 | CLK1 (0.44) | LCKKDRPIM1TGFBR1 | |
| SCHEMBL17814123 | 0.72 | FGFR1 (0.44) | CYP11B1CYP11B2LCKKDM1A | |
| SCHEMBL17814079 | 0.72 | CCNC (0.42) | CYP11B1CYP11B2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| WO-2016089800-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | CYP11B1 1/4885CYP11B2 3/4885RIPK2 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.